Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CKS1B | P61024 | 1/20 | 0.37 |
| ▸ | SKP1 | P63208 | 1/20 | 0.37 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
| ▸ | DKK1 | O94907 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 4/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.34 |
| ▸ | ACACB | O00763 | 2/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL715569 | 0.84 | CKS1B (0.39) | POLBCKS1BSKP1SKP2CREBBP | |
| SCHEMBL715571 | 0.84 | CKS1B (0.39) | POLBCKS1BSKP1SKP2CREBBP | |
| SCHEMBL715570 | 0.84 | CKS1B (0.39) | POLBCKS1BSKP1SKP2CREBBP | |
| SCHEMBL2115276 | 0.82 | CKS1B (0.37) | POLBCKS1BSKP1SKP2CREBBP | |
| SCHEMBL16666212 | 0.82 | SUV39H2 (0.41) | CKS1BSKP1SKP2ABL1PDCD1 | |
| SCHEMBL16666211 | 0.82 | SUV39H2 (0.41) | CKS1BSKP1SKP2ABL1PDCD1 | |
| SCHEMBL16666213 | 0.82 | SUV39H2 (0.41) | CKS1BSKP1SKP2ABL1PDCD1 | |
| SCHEMBL2114946 | 0.80 | CCNT1 (0.37) | PDCD1CD274 | |
| SCHEMBL15899855 | 0.80 | CNR2 (0.39) | CNR2 | |
| SCHEMBL15899849 | 0.80 | CNR2 (0.39) | CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095005-A1 | Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095005-A1 | Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors | PI4KA, PDPK1, PIK3CA | POLB 668/4885CKS1B 449/4885SKP1 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.